From the Wires
Prima BioMed Announces Two Accepted Abstracts for Presentation at ISCT Annual Meeting
By: Marketwired .
Feb. 3, 2013 11:30 PM
SYDNEY, AUSTRALIA -- (Marketwire) -- 02/03/13 -- Prima BioMed Ltd (ASX: PRR) (NASDAQ: PBMD) (ISIN: US74154B2034) ("Prima", "the Company") announces that two abstracts related to research and development of CVac have been accepted by the International Society for Cellular Therapy (ISCT) for presentation at its 19th annual meeting in Auckland, New Zealand from 22-25 April 2013.
The two poster presentations are;
Dr. Gargosky's poster will describe the use of intracellular cytokine staining (ICS) assays to measure mucin 1-specific T cells in patient's peripheral blood mononuclear cells (PBMC). Dr. Buchholtz's poster will describe the process of developing and qualifying the COSTIM assay to assess the potency of a product like CVac.
Both posters will be presented during the Immunotherapy, Regenerative Medicine, Translational Process Development and Gene Therapy session on Wednesday, 24 April 2013 from 5:00pm to 6:30pm.
About Prima BioMed
For further information please contact:
Latest AJAXWorld RIA Stories
Subscribe to the World's Most Powerful Newsletters
Subscribe to Our Rss Feeds & Get Your SYS-CON News Live!
SYS-CON Featured Whitepapers
Most Read This Week